Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of aliskiren + amlodipine in essential hypertension
2006-003629-98Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aliskiren and amlodipine in essential hypertension, sponsored by Novartis. Started Sep 2006; status: completed.
02
Drugs
aliskirenamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2006-003629-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003629-98.